ARCHIVED - Recommendations on a Human Papillomavirus Immunization Program

 

Appendix 2: Table 1b

Table 1b: HPV vaccine cost-effectiveness studies, base case assumptions

Assumption

Sanders(36)

Kulasingam(35)

Goldie(38)

Brisson(40)

Taira(30)

Elbasha(32)

Marra(34)

Reduction in cervical cancer-related mortality

21%

_

_

_

_

_

_

Reduction in cervical cancer cases

20%

15%

60%

62%

62% female
64% female & male

78% female
91% female & male

14% female F14

Reduction in
precancer lesions
CIN 1

_

_

_

24%

_

_

_

CIN 2/3

21%

_

_

47%

_

_

_

Reduction in HPV infections

13%

_

_

_

95% female
99% female & male

_

75% female F14

Costs
 
No vaccination

$39,682

$822

$1,111

_

$40,423

$72,659,302

$1,368,958,619

Vaccination

$39,928

$973

$1,400

7.2 million (Q)

$40 667

$74,042,990

$1,657,060,138

Change in Cost

$246

_

$289

4.4 million (B)

$244

$1,383,687

$288,101,519

               
Life years gained
 
No vaccination

28.785 yr

28.756 yr

_

_

28.798 yr

_

_

Vaccination

28.793 yr

28.758 yr

_

_

28.811 yr

_

_

Change in LYG

2.8 yr

_

_

1,321 yr

5.0 yr

_

_

               
Quality-adjusted life years gained
 
No vaccination

27.720 yr

_

25.982 yr

_

27.742 yr

2,698,711 yr

49,370,060 yr

Vaccination

27.731 yr

_

25.993 yr

_

27.759 yr

2,699,178 yr

49,381,805 yr

Change in QALY

4.0 yr

_

_

1,079 yr

6.1 yr

467 yr

11,744 yr

Cost/LYG

$32,066

$92,667

_

$34,496

$17,802

_

_

Cost/QALY

$22,755

_

$24,300

$20,512 Q
$31,060 B

$14,583 female
$442,039 female & male

$2,964 female
Dominated for
female & male

$24,530 female F14
$167,364 female & male

*SIL = squamous intraepithelial lesion, CIN = cervical intraepithelial neoplasia, LSIL = low-grade squamous intraepithelial lesion, HSIL = high-grade intraepithelial lesion

Page details

Date modified: